LPC
MDCO

Lion Point Capital’s Medicines Co MDCO Stock Holding History

Lion Point Capital’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-783,950
Closed -$66.6M – 31
2019
Q4 		$66.6M Hold
783,950
– – 6.18% 5
2019
Q3 		$39.2M Buy
783,950
+283,250
+57% +$11.3M 4.37% 8
2019
Q2 		$18.3M Buy
500,700
+350,700
+234% +$11.4M 1.8% 14
2019
Q1 		$4.19M Buy
+150,000
New +$3.54M 0.38% 20
2018
Q4 		– Sell
-727,205
Closed -$21.8M – 39
2018
Q3 		$21.8M Hold
727,205
– – 2.04% 12
2018
Q2 		$26.7M Buy
727,205
+425,000
+141% +$13.8M 2.4% 11
2018
Q1 		$9.95M Buy
302,205
+215,204
+247% +$6.72M 0.91% 19
2017
Q4 		$2.38M Hold
87,001
– – 0.21% 33
2017
Q3 		$3.22M Hold
87,001
– – 0.33% 27
2017
Q2 		$3.31M Buy
+87,001
New +$3.87M 0.46% 24

Other funds holding MDCO

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Lion Point Capital's MDCO Position: Q1 2020 in Review

Lion Point Capital sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 783,950 shares — an estimated $66.6M sold.

Lion Point Capital first reported a position in MDCO in Q2 2017 and held it in 10 quarters. The position peaked at $66.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • Lion Point Capital reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • Lion Point Capital sold 783,950 Medicines Co shares in Q1 2020, an estimated $66.6M.
  • Lion Point Capital first reported a position in Medicines Co in Q2 2017 and held it in 10 quarters.
  • Lion Point Capital's Medicines Co position peaked at $66.6M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Lion Point Capital's 13F filing for Q1 2020, filed 15 May 2020.